Medindia

X

FDA Approves New Drug Eylea for Blindness

by Dr. Trupti Shirole on  November 20, 2011 at 6:11 PM Drug News   - G J E 4
Regeneron Pharmaceuticals Inc.'s drug Eylea, an injection designed to treat neovascular or 'wet' age-related macular degeneration, a leading cause of blindness in older people has been approved by the FDA. Eylea is the first competitor to Basel, Switzerland-based Roche's Lucentis. Its approval boosts the number of Regeneron's marketable products to two.
 FDA Approves New Drug Eylea for Blindness
FDA Approves New Drug Eylea for Blindness
Advertisement

Regeneron's CEO says Eylea will be available to patients within days. Eylea will be injected every 8-weeks, half as often as Lucentis. It is expected to capture 16% of market from Lucentis.

Advertisement
Eylea may cost $1,950 per injection. The drug will hit peak sales of $1.1 billion by 2021.


Source: Medindia
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All